Novo Nordisk NVO, the pharmaceutical big behind standard semaglutide medication like Ozempic, Rybelsus, and Wegovy, is making a major authorized push to stop the sale of semaglutide knockoffs within the U.S., Rolling Stone studies.
Authorized Battle Towards Knockoffs
In keeping with the lawsuits reviewed, Novo Nordisk is accusing different well being organizations of illegally promoting semaglutide, which they declare constitutes a trademark infringement. The corporate argues that since there isn’t any authorised generic model, anybody promoting semaglutide is in violation of state rules in opposition to untested drugs.
Novo Nordisk’s Stance
“Federal and state legislation require approval for brand spanking new medication for good purpose. Drug approval is evidence-based, and it’s important to make sure the standard, security, and effectiveness of recent medication,” the authorized complaints learn.
A spokesperson for Novo Nordisk emphasised the corporate’s concentrate on affected person security, stating that generic makes an attempt at semaglutide have “created a excessive danger of client confusion and deception in addition to potential security issues.”
See Additionally: Famed Weight Loss Drug Wegovy By Novo Nordisk Sees Important Drop In Lengthy-Time period Use, Research Reveals
Affected persons’ Perspective
Regardless of warnings about potential reactions, sufferers have expressed their willingness to proceed utilizing the remedy attributable to excessive costs. They argue that if compounded medication are secure for life-threatening allergic reactions, they need to be secure for weight reduction as properly.
Monetary Implications
Whereas Novo Nordisk insists on affected person security, there’s additionally a monetary element to the lawsuits. The corporate argues that ignoring drug-approval necessities supplies an unfair aggressive benefit over pharmaceutical producers like themselves.
Learn Subsequent: Miracle Weight Loss Drug Ozempic Has A Counterfeit In The Market, However It Has Life-Threatening Penalties
Picture through Shutterstock
Hello, I’m the Benzinga Newsbot!
I generated the above abstract, using the sources I hyperlinked above. For a extra complete understanding of the subject, I like to recommend you to learn the complete article.
This abstract was reviewed by Benzinga editors in keeping with the publication’s editorial tips earlier than being printed.
